Login / Signup

A single-dose of intranasal vaccination with a live-attenuated SARS-CoV-2 vaccine candidate promotes protective mucosal and systemic immunity.

Awadalkareem AdamBirte KalveramJohn Yun-Chung ChenJason YeungLeslie RodriguezAnkita SinghPei-Yong ShiXuping XieTian Wang
Published in: bioRxiv : the preprint server for biology (2023)
An attenuated SARS-CoV-2 virus with modified viral transcriptional regulatory sequences and deletion of open-reading frames 3, 6, 7 and 8 (∆3678) was previously reported to protect hamsters from SARS-CoV-2 infection and transmission. Here we report that a single-dose intranasal vaccination of ∆3678 protects K18-hACE2 mice from wild-type or variant SARS-CoV-2 challenge. Compared with wild-type virus infection, the ∆3678 vaccination induces equivalent or higher levels of lung and systemic T cell, B cell, IgA, and IgG responses. The results suggest ∆3678 as an attractive mucosal vaccine candidate to boost pulmonary immunity against SARS-CoV-2.
Keyphrases
  • sars cov
  • wild type
  • respiratory syndrome coronavirus
  • transcription factor
  • gene expression
  • pulmonary hypertension
  • type diabetes
  • insulin resistance
  • oxidative stress
  • ulcerative colitis
  • skeletal muscle
  • adipose tissue